SEC Form 4 · accession 0001358403-16-000208
BELLICUM PHARMACEUTICALS, INC · BLCM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Annemarie Moseley
Officer — COO/EVP Clinical Development
Period of report
Jun 2, 2016
Accepted (ET)
Jun 6, 2016 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358403
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 2, 2016 | M | 18,235 | $2.55 | A | 18,486 | D | |
| Common Stock | Jun 2, 2016 | S | 18,235 | $13.00 | D | 251 | D | |
| Common Stock | Jun 2, 2016 | M | 6,765 | $2.55 | A | 7,016 | D | |
| Common Stock | Jun 2, 2016 | S | 6,765 | $13.00 | D | 251 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $2.55 | Jun 2, 2016 | M | 18,235 | D | — | Nov 8, 2021 | Common Stock | 18,235 | 0 | D |
| Stock Option (right to buy)F3 | $2.55 | Jun 2, 2016 | M | 6,765 | D | — | Nov 25, 2022 | Common Stock | 6,765 | 52,058 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2015.
- F225% of the shares subject to the stock option vested and became exercisable on November 9, 2012, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- F325% of the shares subject to the stock option vested and became exercisable on November 26, 2013, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.